Form 4: NeoGenomics Director Equity Transaction Update

Director Felicia Williams exercised restricted stock units and received new equity grants in NeoGenomics Inc.

Summary

• Director Felicia Williams acquired 23,077 shares of common stock through the vesting and exercise of restricted stock units (RSUs) on June 1, 2026.
• The reporting person received a new grant of 11,069 stock options with an exercise price of $10.52.
• The reporting person received a new grant of 15,970 restricted stock units.
• Following these transactions, the director's total direct beneficial ownership of common stock is 30,237 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity ownership changes.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.
• Equity-based compensation structure incentivizes long-term performance for board members.

Negatives

• None identified; this is a standard compensatory equity transaction for a director.

Risks

• Future value of equity grants is subject to market volatility and the company's stock price performance.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a disclosure of director equity transactions.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the biotechnology and diagnostics sector to ensure board alignment with shareholder value creation.

Comparison to Industry Standards

• The equity compensation structure is consistent with standard corporate governance practices for mid-cap healthcare companies.
• The use of both stock options and RSUs is a common retention and incentive strategy for board members in the life sciences industry.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensatory equity grants.

Next Steps

• Future vesting of the newly granted 15,970 RSUs and 11,069 stock options.

Key Dates

Keywords

NeoGenomics, NEO, Form 4, Insider Trading, Equity Compensation, Director Ownership